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To investigate the anti-fibrotic effects of the traditional oriental herbal medicine 
Daikenchuto (DKT) associated with transient receptor potential ankyrin 1 (TRPA1) 
channels in intestinal myofibroblasts.  
 
METHODS 
Inflammatory and fibrotic changes were detected in a 2,4,6-trinitrobenzenesulfonic acid 
(TNBS) chronic colitis model of wild-type and TRPA1-knockout (TRPA1-KO) mice via 
pathological staining and immunoblotting analysis. Ca2+ imaging experiments examined 
the effects of DKT and its components/ingredients on intestinal myofibroblast (InMyoFib) 
cell TRPA1 channel function. Pro-fibrotic factors and transforming growth factor 
(TGF)-β1-associated signaling were tested in an InMyoFib cell line by qPCR and 
immunoblotting experiments. Samples from non-stenotic and stenotic regions of the 
intestines of patients with Crohn’s disease (CD) were used for pathological analysis. 
 
RESULTS  
Chronic treatment with TNBS caused more severe inflammation and fibrotic changes in 
TRPA1-KO than in wild-type mice. A one-week enema administration of DKT reduced 
fibrotic lesions in wild-type but not in TRPA1-KO mice. The active ingredients of DKT, i.e., 
hydroxy α-sanshool and 6-shogaol, induced Ca2+ influxes in InMyoFib, and this was 
antagonized by co-treatment with a selective TRPA1 channel blocker, HC-030031. DKT 
counteracted TGF-β1-induced expression of Type I collagen and α-smooth muscle actin 
(α-SMA), which were accompanied by a reduction in the phosphorylation of Smad-2 and 
p38-mitogen-activated protein kinase (p38-MAPK) and the expression of myocardin. 
Importantly, 24-h incubation with a DKT active component Japanese Pepper increased the 
mRNA and protein expression levels of TRPA1 in InMyoFibs, which in turn negatively 
regulated collagen synthesis. In the stenotic regions of the intestines of CD patients, TRPA1 







The effects of DKT on the expression and activation of the TRPA1 channel could be 
advantageous for suppressing intestinal fibrosis, and benefit inflammatory bowel disease 
treatment. 
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Core tip: Active ingredients of the famous Chinese medicine Da-Jian-Zhong-Tang 
(Daikenchuto; DKT), i.e., hydroxy α-sanshool and 6-shogaol, induced Ca2+ influxes in 
intestinal myofibroblast (InMyoFib), which were antagonized by co-treatment with a 
selective transient receptor potential ankyrin 1 (TRPA1) channel blocker HC-030031. DKT 
counteracted the transforming growth factor (TGF)-β1-induced expression of Type I 
collagen, α-smooth muscle actin (α-SMA), and this was accompanied by a reduction in 
fibrosis signaling downstream of the TGF-β1 receptor. Importantly, a 24-h incubation with 
another DKT active ingredient of Japanese Pepper increased mRNA and protein expression 
in TRPA1, which in turn negatively regulated collagen synthesis in InMyoFibs. In stenotic 
regions of the intestines of patients with Crohn’s disease, TRPA1 expression was 
significantly increased. 
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fibrosis by activating myofibroblast transient receptor potential ankyrin 1 channel. World J 






Daikenchuto (DKT; Da-Jian-Zhong-Tang in Chinese) is a traditional herbal medicine, 
originally described in Jin Gui Yao Lue (“Essential Prescriptions from the Golden Cabinet”), 
a classic book of Chinese medicine published more than 1800 years ago. DKT is often used 
for postoperative ileus and constipation, and is composed of several crude components, 
Zingiberis rhizoma (Ginger), Panax ginseng (Ginseng; Ginseng radix), Zanthoxyli fructus 
(Japanese pepper), and malt sugar. DKT generally accelerates gastrointestinal motility; it 
increases intestinal blood flow and gastrointestinal hormone secretion[1-3]. Numerous basic 
studies have demonstrated the effects of DKT on vasodilation, inflammation, and bacterial 
translocation[4-9]. Ginger contains several active ingredients, such as gingerols and shogaols 
(6-, 8-, and 10- isomers), which have anti-inflammatory and vasoprotective effects via 
modulating the activities of mitogen-activated protein kinase (MAPK), protein kinase B 
(Akt), and NF-κB[10-12]. Japanese pepper contains hydroxy-α and hydroxy-β-sanshools that 
alter intestinal blood flow, motility, and barrier function by inducing the 
synthesis/secretion of adrenomedullin and calcitonin gene-related peptides[1,13]. DKT 
accelerates the recovery of gastrointestinal function in patients undergoing an open 
colectomy for colon cancer[14,15]. However, the essential pharmacological mechanism(s) 
underlying these effects remains largely unclear.  
  Myofibroblasts are crucial for the pathogenesis of tissue fibrosis. The formation of stress 
fibers in activated myofibroblasts results in the release of a myocardin-related transcription 
factor, a transcriptional coactivator of serum response factor. The major pro-fibrotic factor, 
transforming growth factor (TGF)-β, secreted from many types of cells, induces or 
augments myofibroblast functions, i.e., transformation, proliferation, invasion, migration, 
stress fiber formation, and collagen synthesis[16,17]. Previously, we used an intestinal 
myofibroblast (InMyoFib) cell line, stimulated by TGF-β1, to produce a pathological fibrosis 
model[18]. TGF-β1 treatment induced dramatic morphological changes in myofibroblasts, 
including an enlarged shape and a filamentous microstructure characteristic in transformed 
cells[19]. The activated TGF-β receptor 1 (TGFR) complex phosphorylates the transcription 





signal through non-canonical pathways involving extracellular signal-regulated kinases 
(ERKs), c-Jun N-terminal kinases, and p38-MAPK. Both pathways are implicated in 
myofibroblast-mediated cytokine production and fibrosis in the gut[21,22]. Levels of TGF-β 
were found to be elevated in the inflamed intestines of patients with Crohn’s disease (CD) 
and ulcerative colitis. TGF-β1 is also essential for anti-inflammatory responses. Thus, there 
is a caveat against the use of a TGF-β1-neutralizing strategy for anti-fibrotic treatment in 
clinical practice, as TGF-β1-neutralizing antibodies might exacerbate the progression of CD 
by attenuating the anti-inflammatory actions of TGF-β1. Further, abnormal TGF-β signaling 
was reported to impair intestinal immune tolerance and tissue repair[23].  
  There is mounting evidence for the role of transient receptor potential (TRP) channels in 
a variety of cellular remodeling processes[24-27]. For instance, TRPA1 is expressed not only in 
peripheral sensory neurons, but also in intestinal epithelial cells[7,28]. The TRPA1 agonist 
allyl isothiocyanate (AITC) exhibits anti-fibrogenic effects in hepatic stellate cells, and 
another TRPA1 agonist allicin prevents fibrotic changes in the oral submucosa and 
heart[29,30]. Our recent study also demonstrated that TRPA1 mediates the anti-fibrotic effects 
of steroids and pirfenidone in the mouse TNBS-colitis model, and TRPA1 expression is 
significantly increased in the intestinal stenotic regions of CD patients[18]. Moreover, TRPA1 
activity has been ascribed to anti-inflammatory responses in dextran sulfate 
sodium-induced chronic colitis, where TRPA1 regulates the inflammatory potential of T 
cells[31]. A later study based on interleukin knockout and T-cell-adoptive transfer colitis 
models suggested that TRPA1 likely counteracted the transient receptor potential vanilloid 
type 1 (TRPV1)-mediated differentiation of CD4+-T cells into Th1-effector cells[32]. Finally, 
TRPA1 activation by cannabichromene was found to reduce the severity of dinitrobenzene 
sulfonic acid (DNBS)-induced colitis[33]. 
  Hydroxy-α-sanshool and 6-shogaol are the active ingredients of DKT components ginger 
and Japanese pepper. Both are capable of activating TRPA1 and TRPV1 channels[34,35]. 
Activation by DKT of the TRPA1 channel endogenously expressed in intestinal epithelial 
cells improves gastrointestinal microcirculation via adrenomedullin release[28], and 





  Currently, surgical operation is the only available option that prevents the fibrotic 
complications of CD, but it often only has temporary benefits. It is, therefore, crucial to 
develop new alternative treatments for fibrotic stenosis. Recently, DKT has often been used 
to mitigate inflammatory bowel disease-associated fibrosis and the resulting stenosis and 
strictures, common and severe complications in CD patients. However, the pathogenesis of 
CD-related fibrosis and how DKT exerts its therapeutic effects are poorly understood[37]. 
In this study, we tested whether DKT can activate myofibroblast TRPA1 channels to 
reduce TGF-β1-induced fibrotic events. To this end, we examined the effects of DKT and its 
ingredients on TRPA1 channel activity and the expression of pro-fibrotic factors 
downstream of the TGF-β1 signaling pathway. Moreover, surgical samples from stenotic 
and non-stenotic regions of the intestines of patients with CD were used to confirm the 
validity of the observations in cell experiments for human pathogenesis. 
  
MATERIALS AND METHODS 
Materials 
DKT is an aqueous extract containing processed ginger, ginseng (ginseng radix), and 
Japanese pepper at a ratio of 5:3:2. The dried powdered extract forms of DKT (TU-100: 
without maltose syrup), ginger, ginseng, and Japanese pepper were obtained from 
Tsumura Co. (Tokyo, Japan). These extracted powders were dissolved in ethanol by 
sonication and purified by filtering. Ginsenoside (Wako, Japan), 6-shogaol (Wako, Japan), 
hydroxy-α-sanshool (Adipogen Life Science), AITC, and HC-030031 (Sigma–Aldrich, St 
Louis, Missouri, United States) were also used in this study. Recombinant human TGF-β1 
(Wako) and Type I collagen (IFP, Higashine, Japan) were added to cultured cells, as 
indicated by the manufacturer’s instructions. Human stealth siRNAs for TRPA1: 
TRPA1HSS113276 (5′-GGAGCAAUUGCUGUUUACUUCUAUU-3′ and 
5′-AAUAGAAGUAAACAGCAAUUGCUCC-3′) were obtained from Invitrogen (Carlsbad, 
California, United States) and used for gene silencing, according to the manufacturer’s 
instructions. Other TRPA1-siRNAs, TRPA1HSS113277 and TRPA1HSS189723, were also 





Antibodies against TRPA1 (mouse; Sigma–Aldrich), α-SMA (Abcam, Cambridge, United 
States), β-actin (Abcam, Cambridge, United States), Collagen I (Abcam, Cambridge, United 
States), Smad-2/3, phospho-Smad-2, and p38-MAPK (Cell Signaling Technology, Beverly, 
MA, United States) were used for immunoblotting and immunostaining experiments. An 
ELISA Kit was used to measure the Type I collagen levels in the conditioned medium. 
 
Trinitrobenzenesulfonic acid chronic colitis model  
Chronic TNBS-associated colitis was induced as previously reported[18]. TNBS intracolonic 
administration for mice (8–9 weeks old, n = 8) was achieved after 24-h fasting by inserting a 
polyethylene catheter 4 cm into the rectum under pentobarbital (40 mg/kg injected i.p. with 
saline) anesthesia. TNBS solution in 30% ethanol/phosphate-buffered saline (PBS) (10 
mg/mL; 50 μL) and sonicated was weekly injected for six weeks, as illustrated in Figure 1A. 
The vehicle control group received 30% ethanol/PBS (50 μL). DKT was administered daily 
(5 mg/kg/day; anesthetized by isoflurane) by enema for one week after the last TNBS 
treatment. Colonic tissues were excised from the anus to the caecum at week six after 
cervical dislocation. All animal experiments were conducted in accordance with the 
guidelines of the Animal Center of Fukuoka University. 
 
Histological evaluation 
The mouse distal colon and patient samples were fixed in 10% buffered formalin, 
embedded in paraffin, and cut into 4-μm-thick sections for routine hematoxylin–eosin (HE) 
and Masson’s trichrome (MT) staining. Stained colon tissues were micro-photographed at 
200 × magnification on six randomly chosen locations of each tissue, and analyzed by a 
pathologist (Koga K) in a blinded manner. For all mice, the fibrosis score was measured at 
the tissue located 1 cm from the anus, where the most obvious fibrosis was observed. The 
optical density of the blue-stained collagen fibers was measured and expressed as a fibrosis 
score on a scale of 0–3: (0) no fibrosis wild-type vehicle control mouse; (1) mild fibrosis; (2) 






Cell culture  
Normal human intestinal myofibroblasts (InMyoFibs) were purchased from Lonza 
(CC-2902; Basel, Switzerland) and grown in smooth muscle basal medium (SmBM), 
supplemented with 5% fetal bovine serum (FBS), antibiotics (gentamicin/amphotericin-B), 
and growth factors (insulin, human epidermal growth factor-, and human fibroblastic 
growth factor). InMyoFibs were passaged 10–19 times. TGF-β1 (5 ng/mL) was used under 
low serum (1% FBS) conditions.  
 
Electrophysiological study  
Whole-cell voltage clamp recording was implemented by an EPC-10 patch-clamp amplifier 
(HEKA Electronics, Lambrecht, Pfalz, Germany). The recording electrodes (patch pipettes), 
with resistances of 2–4 MΩ, were fabricated from borosilicate glass capillaries. An Ag–AgCl 
wire was used as a grounding electrode. Capacitive currents were electronically 
compensated, and the linear leak and residual capacitance were subtracted. More than 70% 
of series resistance was compensated to minimize voltage errors.  
  Data analysis and illustration were performed offline using the versatile analysis 
software programs Clampfit v.9.2 (Axon Instruments, Foster City, United States) and 
KaleidaGraph v.4.0 (Hulinks, Tokyo, Japan). Long-term recordings were performed at a 
sampling rate of 100 Hz in conjunction with an A/D, D/A-converter PowerLab/400 
(ADInstruments, Australia) and analyzed by the accessory software LabChart v.8.1.5. A 
solenoid valve-driven fast solution change device similar to the ‘Y-tube' system was used to 
rapidly apply drugs onto cells as previously described[38]. The density of the membrane 
current (pA/pF) was calculated by normalizing its amplitude by the cell capacitance to 
minimize cell size-dependent variations. To prevent the quick Ca2+-dependent inactivation 
of TRPA1 currents, a Ca2+ chelator BAPTA was added to both the bath and pipette 
solutions[39].  
The bath solution contained 140 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl2, 5 
mmol/L EGTA, 10 mmol/LHEPES, and 10 mmol/L glucose (pH = 7.4, adjusted with Tris 





Patch pipettes were filled with 130 mmol/L Cs-aspartate, 10 mmol/L TEA-Cl, 5 mmol/L 
BAPTA, 1.374 mmol/L Ca-gluconate, 1 mmol/L MgCl2, 2 mmol/L MgSO4, 2 mmol/L 
Na2ATP, and 10 mmol/L HEPES (pH = 7.2, adjusted with Tris base). 
 
Measurement of [Ca2+]i  
The intracellular Ca2+ concentration ([Ca2+]i) of myofibroblasts was monitored using a 
digital fluorescence imaging technique with Fura-2. Briefly, InMyoFibs were enzymatically 
dispersed and lodged on a poly-L-lysine-coated (Sigma–Aldrich, United States) glass 
chamber placed on the stage of an inverted fluorescent microscope (DMI600B; Leica, 
Germany). InMyoFibs cells were then loaded with 5 µmol/L Fura-2/AM in the dark at 
20-25 °C for 30 min. The intensities of Fura-2 emissions at 510 nm (± 10 nm) resulting from 
excitation at 340 or 380 nm were measured through a fluorescent microscope (DMI600B) 
and a Cascade EMCCD camera (Nippon Roper, Tokyo, Japan). Data acquisition and 
analysis were performed using SlideBook v.4.2 software (Intelligent Imaging Innovation 
Inc., Denver, Colorado, United States). Fluorescence intensities were corrected for 
background fluorescence, and changes in [Ca2+]i were defined as the ratio of corrected 
fluorescence intensities at 340 and 380 nm excitations (F340/F380). The normal external 
solution for Ca2+-imaging experiments contained 140 mmol/L NaCl, 5 mmol/L KCl, 1 
mmol/L CaCl2, 1.2 mmol/L MgCl2, 10 mmol/L HEPES, and 10 mmol/L glucose (pH = 7.4, 
adjusted with Tris base). 
 
Immunostaining 
InMyoFibs cells were fixed in 4% formaldehyde for 15 min and permeabilized with 0.3% 
Triton X-100 in 5% normal goat serum (Wako). Cells were then incubated overnight with 
primary antibodies (1:200 dilution) against α-SMA at 4 °C, washed with PBS, and incubated 
with an Alexa Fluor-conjugated secondary antibody (Life Technologies, Carlsbad, 
California, United States, 1:200 dilution) for an additional 1 h. Immunostained cells were 
analyzed using a Zeiss LSM 710 Confocal Microscope (Oberkochen, Germany). Images 





intensity, and detector gain. 
 
Real-time RT-PCR  
Total RNA was extracted from InMyoFibs using the RNeasy RNA Extraction Kit (Qiagen, 
Venlo, Netherlands). To quantify mRNA expression levels, real-time PCR was performed 
using a BioMark™ HD System (Fluidigm, South San Francisco, California, United States). 
Thermocycling was performed using an initial denaturation at a hot start phase of 60 s at 
95 °C. This was followed by 35 cycles of 5 s at 96 °C and 20 s at 60 °C. The following 
TaqMan® Gene Expression Assay kits from Life Technologies were used for real-time PCR 




Immunoblotting experiments were performed to examine the protein levels of Type I 
collagen, α-SMA, β-actin, Smad-2/3, phospho-Smad-2, and p38-MAPK in InMyoFibs, as 
described previously[19]. Total cell lysates were homogenized in radioimmunoprecipitation 
assay buffer with protease inhibitors, and prepared in a sample buffer and diluted in 5% 
(v/v) 2-mercaptoethanol and 1% (w/v) bromophenol blue prior to electrophoresis. Proteins 
were resolved using 10% (w/v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), and transferred to polyvinyldifluoridine (PVDF) membranes. The membranes 
were blocked with Blocking One (Nacalai Tesque, Kyoto, Japan) and incubated overnight 
(at 4 °C) with the appropriate primary antibodies. The protein levels were detected by 
incubating the PVDF membranes with appropriate species-specific, horseradish 
peroxidase-conjugated secondary antibodies (20-25 °C, 45 min), and visualized using the 
ECL Western Blotting Detection System (GE Healthcare, Little Chalfont, United Kingdom). 
 
Patient samples 
We obtained surgical samples from three male CD patients with colonic lesions with a 





15–26 years). All patients had suffered, in addition to coexisting stenosis, an 
intra-abdominal or perianal fistula and/or abscess, during the course of the disease. All 
patients received an anti-TNF agent. The Fukuoka University Hospital Ethics Committee 
approved the protocol, and written informed consent was obtained from all patients. 
 
Statistical analysis 
Results are expressed as means ± SEM. Experimental protocols were repeated with at least 
four different batches of cells under each condition, and pooled data were averaged and 
subjected to statistical analyses. Statistically significant differences among groups were 
evaluated by analysis of variance (ANOVA), and Dunnett’s test was employed for multiple 
comparisons. P-values < 0.05 were considered statistically significant.  
 
RESULTS 
Chronic TNBS fibrosis model of TRPA1-KO mice  
To better visualize the time course of chronic colitis, we adopted the TNBS-induced colitis 
model, as it is known to allow a more moderate and slower progression of gut 
inflammation and fibrosis in mice than the other colitis models.  
  At the sixth week of TNBS treatment, TRPA1-KO mice showed more severe signs of 
inflammation/fibrosis than did wild-type mice, where prominent cell infiltration occurred 
in some mucosal and submucosal layers. The co-administration of DKT reduced these 
pathological changes in wild-type (WT), but not in TRPA1-KO mice (Figure 1B). 
Concomitantly, the Type I collagen protein expression and fibrosis score, which were 
remarkably enhanced and aggravated by TNBS treatment, respectively, were significantly 
reduced in WT but not in TRPA1-KO mice (Figure 1B, 2A, 2B). Double immunostaining 
experiments indicated a high co-incidence of immunoreactivities against TRPA1 and heat 
shock protein (HSP) 47, an endoplasmic reticulum-resident molecule essential for correct 
procollagen folding[18]. The number of TRPA1/HSP47-double-positive cells per unit area 
greatly increased in the TNBS-treated groups compared to in the vehicle control group 






DKT activates TRPA1 channel and antagonizes fibrotic changes in InMyoFibs 
We next examined the ability of DKT to induce TRPA1 activity in InMyoFib. The workflow 
for ethanol extraction of crude components from DKT, i.e., ginger, ginseng radix, and 
Japanese pepper, are shown in Figure 3A. In the whole-cell mode of patch-clamp recording 
(holding potential: −60 mV), a potent TRPA1 agonist, AITC (10 μmol/L), induced a robust 
non-selective cation current. This current was strongly inhibited by a TRPA1-selective 
antagonist, HC-030031 (10 μmol/L) (Figure 3B). The same concentration of AITC also 
evoked a prominent rise in [Ca2+]i, which was completely inhibited by the application of 
HC-030031 (10 μmol/L)[18]. A similar-magnitude rise in HC-030031-sensitive [Ca2+]i was 
also induced by DKT (0.1% EtOH extract) (Figure 3C). These results suggest that InMyoFibs 
express functional TRPA1 channels with Ca2+ permeability, which can be activated by DKT. 
  We then examined how DKT affects the fibrotic changes induced by TGF-β1 treatment. 
As shown in Figure 3D, the 24-h treatment of InMyoFibs with 5 ng/mL TGF-β1 facilitated 
stress fiber formation and protein expression of α-SMA, which was effectively suppressed 
by co-treatment with 0.1% EtOH extract of DKT. Concomitantly, the 24-h treatment of 
InMyoFibs with 5 ng/mL TGF-β1 enhanced the mRNA expression levels of the master 
transcription regulator MYOCD, α-SMA (ACTA2), collagen Type I alpha 1 (COL1A1), and 
Type I collagen released in the culture medium. DKT (0.01%, 0.1% EtOH extract) effectively 
suppressed these mRNA upregulations in a dose-dependent manner (Figure 3E–G). In 
addition, DKT (0.001%, 0.01%, 0.1% EtOH extract) did not affect the mRNA levels of 
COL1A1 in the absence of TGF-β1 stimulation, but 100 µg/mL DKT suppressed Type III 
collagen gene (COL3A1) expression, irrespective of TGF-β1 treatment (data not shown). 
 
Active components and ingredients of DKT activate TRPA1 and show anti-fibrotic effects 
We next examined the efficacies of the active components and ingredients contained in 
DKT. Among the three active components of DKT (ginger, ginseng, Japanese pepper), 
ginger was the most effective, showing a similar efficacy to DKT (Figure 4A). In contrast, 





effect (Figure 4C and 4E, respectively). The Ca2+ mobilizing effects of ginger and Japanese 
pepper were almost completely antagonized by the prior application of a selective TRPA1 
channel blocker HC-030031, suggesting the involvement of TRPA1 activation (Figure 4A, C, 
and E). The active ingredients of the respective DKT components were further examined by 
the same Ca2+-imaging protocol as used above. The active ingredient of ginger, 6-shogaol 
(100 μmol/L), induced a comparable Ca2+ influx to that of AITC (10 μmol/L), while that of 
Japanese pepper, hydroxy α-sanshool (1 μmol/L), induced a much milder influx. The active 
ingredient of ginseng radix, ginsenoside Rb1, was virtually ineffective (Figure 4B, D, and F).  
  We then explored the inhibitory effects of ginger and Japanese pepper on the fibrotic 
changes induced by 24-h treatment with 5 ng/mL TGF-β1. Co-treatment with ginger or 
Japanese pepper significantly suppressed TGF-β1-induced stress (α-SMA) fiber formation 
in InMyoFibs (Figure 4G). In accord with these immunostaining results, ginger, Japanese 
pepper, and AITC all significantly inhibited the TGF-β1-induced mRNA transcriptions of 
α-SMA (ACTA2) and Type I collagen (COL1A1) (Figure 5A and 5B).  
The active ingredient of ginger, 6-shogaol, and that of Japanese pepper, hydroxy 
α-sanshool, also significantly suppressed the TGF-β1-induced increase in COL1A1 mRNA 
expression, with a similar efficacy to that of AITC (Figure 5B, C, and F). The 6-shogaol 
dose-dependently suppressed the Smad-2 phosphorylation and α-SMA mRNA expression 
(ACTA2) induced by TGF-β1 (Figure 5D and 5F). Although ineffective at evoking a rise in 
TRPA1-mediated [Ca2+]i, ginsenoside inhibited the TGF-β1-induced increase in COL1A1 
mRNA expression. 
 
DKT upregulates TRPA1 channel expression  
In another series of experiments, we found that in addition to activating TRPA1 channels, 
DKT also enhanced TRPA1 expression in InMyoFibs. As shown in Figure 6A, 24-h 
incubation with DKT dose-dependently increased TRPA1 mRNA expression in InMyoFibs. 
The TRPA1-upregulating effects were also observed for the DKT components Japanese 
pepper and ginseng radix, but not ginger, and this was particularly prominent when 





enhanced TRPA1 expression in InMyoFibs: when treated with both, they seemingly acted 
additively or synergistically (Figure 6C). In parallel to the upregulation of TRPA1 
expression, the key downstream events of TGF-β1 signaling, phosphorylations of Smad-2 
and p38-MAPK, were also dose-dependently inhibited by the presence of DKT (Figure 6D).  
 
TRPA1 is a negative feedback regulator of collagen synthesis/secretion 
We previously found that extracellular applied collagen downregulated many pro-fibrotic 
gene transcripts involved in TGF-β signaling in InMyoFibs, including CDH2, ACTA2, and 
COL1A1[19]. We therefore examined whether a major extracellular matrix collagen also 
regulated TRPA1 expression. When Type I collagen was added into the culture medium, 
the expression of TRPA1 was enhanced more than two-fold, resulting in the decreased 
endogenous production of collagen (Figure 7A and B). Concomitantly, the expression levels 
of COL1A1, ACTA2, and CDH2 mRNAs in InMyoFibs were downregulated by extracellular 
applied Type I collagen, regardless of the presence of TGF-β1. Moreover, extracellular 
applied collagen caused a significant decrease in TGF-β1-induced MYOCD expression 
(Figure 7B-D). Strikingly, following siRNA knockdown of TRPA1 expression, which 
exacerbated the fibrogenic effects of TGF-β1[18], extracellular applied collagen was no longer 
effective in suppressing the mRNA expression of fibrotic factors COL1A1, MYOCD, ACTA2, 
and CDH2 (Figure 7E). Taken together, these results indicate that TRPA1 activity may be 
commonly involved in anti-fibrotic processes in InMyoFibs, which are activated by DKT 
and extracellular applied collagen.  
 
Enhanced TRPA1 expression in stenotic tissues of CD patients  
Because intestinal stricture formation in CD is driven by a local excessive accumulation of 
myofibroblasts, we examined whether TRPA1 is upregulated in highly fibrotic areas of 
human CD patients. Surgical samples obtained from the patients’ intestines were subjected 
to histological examination and immunostaining. HE and MT staining revealed a much 
denser deposition of collagen fibers in the mucosal layer of the fibrotic stenotic areas than 





diaminobenzidine (DAB) staining was more diffusely distributed in the mucosal and 
submucosal layers of the stenotic regions in the intestines of CD patients (Figure 8). 
 
DISCUSSION 
Daikenchuto (DKT), a traditional oriental herbal medicine, is widely used for the treatment 
of gastrointestinal disorders. DKT is known to improve post-operative complications and is 
frequently prescribed for ileus, abdominal bloating, and cold sensation[40]. Several clinical 
meta-analyses have shown, for instance, that the perioperative administration of DKT 
effectively relieves the symptoms of post-operative ileus in patients undergoing 
gastrointestinal cancer surgery[41]. These beneficial effects of DKT are in part ascribed to its 
multiple actions through differential pharmacokinetics of respective DKT compounds on a 
number of ion channels (TRPA1, TRPV1, two-pore-domain KCNK channels) distributed 
throughout the enteric/myenteric and sensory nerves and intestinal epithelial cells. The 
activation or inhibition of these channels are thought to cause the release of two 
vasoactive/anti-inflammatory peptides, CGRP and adrenomeduline, or enhance the 
excitability of smooth muscle and neurons in the intestine, which improve intestinal 
microcirculation and motility, and induce anti-inflammatory responses[40]. However, 
although a few studies using chronic inflammation models have already reported the 
anti-fibrotic effects of DKT[3,42,43], the critical involvement of intestinal myoblasts in 
fibrogenesis and the therapeutic potential of the myofibroblast TRPA1 channel against it 
have not yet been addressed[18].  
In this respect, the present study has provided several novel findings. First, our TNBS 
colitis model with the comparative use of wild-type and TRPA1-KO mice successfully 
demonstrated the anti-fibrotic actions of DKT via TRPA1 channel activation (Figure 1). 
Specifically, the fibrosis score exacerbated by TNBS treatment was significantly improved 
by enema administration of DKT during the chronic phase of inflammation (i.e., at five 
weeks after TNBS), which was abrogated by the deletion of the trpa1 gene (Figure 2)[18]. 
Second, our in vitro experiments with a human myofibroblast cell line clearly indicated that 





factors/activities by DKT. Additionally, among its components, ginger and Japanese 
pepper, both being able to activate the TRPA1 channel in the expression system, showed 
comparable anti-fibrotic effects. Further investigation of active DKT ingredients suggested 
that 6-shogaol is likely the most effective ingredient, and that hydroxy α-sanshool may also 
mediate some part of DKT’s anti-fibrotic actions (Figures 3–5). Intriguingly, DKT has an 
additional action of enhancing TRPA1 expression per se, which appears to be exerted by its 
Japanese pepper component. Finally, in support of these findings, histological and 
immunohistochemical examinations of human intestinal samples showed that 
myofibroblasts expressing TRPA1, as well as the fibrosis biomarker HSP47, were 
coincidentally accumulated in the stenosis areas of CD patients (Figure 8)[18], as observed in 
the mice TNBS-colitis model (Figure 2C).  
  Taken together, these findings can be interpreted to indicate that in chronically inflamed 
intestines, TRPA1 channel may be antagonistically upregulated in both expression and 
activity against the growing fibrogenic drive, which could further be potentiated by 
TRPA1-stimulating actions of DKT. As we discussed in a recent paper[18], this view could be 
extended to various tissues and organs undergoing chronic inflammation where 
therapeutic activation TRPA1 channels in situ may work beneficially to decelerate locally 
enhanced fibrogenic processes. In fact, there are several lines of evidence that TRPA1 
channels in both neuronal and non-neuronal cells modulate local tissue inflammation 
accompanying fibrotic changes, as exemplified by the animal models of acute pulmonary 
inflammation induced by acrolein and cigarette smoke, experimental colitis, or 
carrageenan-induced paw edema[7,44,45]. 
  In addition to the above findings, we also found that extracellular applied collagen can 
induce the expression of TRPA1, with downregulation of the mRNAs of fibrotic factors 
MYOCD, COL1A1, and ACTA2 (Figure 9). It has been reported that cell contact with 
collagen reduces cadherin expression, which in turn eliminates the mechanotransduction 
between fibroblasts[46]; therefore, extracellular collagen might modulate the expression of 
cadherin and the dynamics of cytoskeleton stress fiber formation via an as-yet-unknown 





study, extracellular collagen application downregulated the expression levels of intrinsic 
collagen, α-SMA, and myocardin, but these changes were not observed in 
TRPA1-siRNA-treated InMyoFibs. These data strongly support the idea that TRPA1 
channel activity is negatively correlated with the collagen synthesis of intestinal 
myofibroblasts. In the context of the present study, this would again represent another type 
of TRPA1-mediated negative feedback regulation that resists against a heightening 
fibrogenic potential.  
  In a few clinical studies, TGF-βl mRNA levels were found elevated in the affected 
intestinal mucosa from the patients with CD and ulcerative colitis, particularly in the 
regions confined to the lamina propria where immune cells, as well as myofibroblasts, 
preferentially reside[23]. Combining this fact with our own finding from human surgical 
samples (i.e., the co-accumulation of TRPA1-/HSP47-double positive myofibroblasts in the 
stenotic regions), it seems plausible to assume that in an interwoven network of 
TGF-β-mediated signaling, TRPA1 in myofibroblasts may operate as a crucial anti-fibrotic 
negative feedback to lower the pathologically increased fibrogenic potential. Thus, 
targeting the myofibroblast TRPA1 signaling axis could be a tenable therapeutic strategy to 
reinforce the anti-fibrotic potential in chronic fibrotic diseases such as CD.  
  The higher prevalence of fibrosis in CD is thought to be the complex consequences of 
transmural bowel inflammation that exposes all mesenchymal cells producing extracellular 
matrix to fibrotic mediators[47]. Therefore, anti-TNF (i.e., anti-inflammatory) treatment is 
generally recommended as the first-line therapy for CD patients with poor prognoses who 
have severe complications or bowel damages[48]. However, anti-TNF treatment has an 
increased risk of worsening stenotic fibrosis[49], and stenotic lesions can be present in 
variable pathological states, such as inflammatory, fibrogenic, and neoplastic, or a 
combination of these states. Therefore, a therapeutic strategy that can distinguish between 
these different states might be more desirable than the currently available 
anti-inflammatory approaches. In this respect, the present finding, that the activation of 
myofibroblast TRPA1 attenuates intestinal fibrosis, may provide great therapeutic benefits, 





lungs, and liver, where several TRP channels, including TRPA1, are highly expressed. 
  Finally, we should point out several limitations of this study. First, the method adopted 
in this study (i.e., TNBS treatment) could not create a severe fibrotic stenosis model, which 
only allowed us to see rather mild fibrotic changes. Second, all biopsy samples were 
obtained from inflammatory bowel disease (IBD) patients but not from healthy donors. If 
this had been done, the results of this study might clinically be more attractive. Third, other 
Chinese medicines that are potentially capable of activating TRPA1 channel were not tested 
in this study. This would somewhat compromise the first priority of DKT for anti-fibrotic 
treatment. In addition, DKT used in this study was obtained from a single source (i.e., 
TSUMURA); therefore, the possibility cannot be entirely excluded that the observed effects 
in this study might differ in details from those obtained with the same drug of a different 
origin. 
  In summary, the present study revealed a new role for myofibroblast TRPA1 channels in 
intestinal fibrosis, i.e., its negative regulation, and showed that DKT upregulates this 
channel protein in both activity and expression to exert its anti-fibrotic actions. These 
findings not only provide a novel molecular target for the anti-fibrotic therapy of 
inflammatory bowel diseases in the future, but also a framework to reinterpret the unique 
theories of traditional Oriental medicine.  
 
 
ARTICLE HIGHLIGHTS   
Research background 
Daikenchuto (DKT) is a traditional oriental herbal medicine, widely used to mitigate 
post-operative ileus and constipation. The mechanism of its actions remains less 
understood, in particular regarding its molecular target(s). However, an important hint to 
addressing this issue has come from our previous findings that the transient receptor 
potential ankyrin 1 (TRPA1) is highly expressed in intestinal myofibroblasts and mediates 







We hypothesized that DKT may activate TRPA1 channels in myofibroblasts to directly 
counteract the fibrotic changes of inflamed intestines. Although DKT has been shown to be 
beneficial for gut motility, intestinal blood flow and gastrointestinal hormone secretion, its 
anti-fibrotic actions through TRPA1 channel activation will be an entirely new finding and 
of considerable clinical significance.  
 
Research objectives 
We aimed at investigating at both in vitro and in vivo levels whether DKT targets TRPA1 
channels expressed in intestinal myofibroblasts to exert its anti-fibrotic actions. The results 
would not only disclose a novel molecular target of anti-fibrotic therapy for inflammatory 
bowel diseases such as Crohn’ disease and ulcerative colitis, but also promote our general 
understanding about the complex actions of herbal medicines.  
 
Research methods 
A trinitrobenzene sulfonic acid (TNBS) chronic colitis model was established in both 
wild-type and TRPA1 knock out mice, in which the impact of DKT administration were 
evaluated by pathological and biochemical analyses. An intestinal myofibroblast cell line 
(InMyoFibs) stimulated by transforming growth factor-β1 (TGF-β1) was used as a cellular 
model of intestinal fibrosis, where expression of TRPA1 and pro-fibrotic factors and related 
intracellular signaling (in particular TGF-β-mediated one) were examined in detail. The 
counteracting effects of DKT on these changes were also evaluated. Biopsy samples from 
non-stenotic and stenotic regions of Crohn’s Disease (CD) patient’s intestines were 
subjected to histological examination and immunoblot analysis with particular respect to 
the altered expression pattern of TRPA1 channel and fibrotic factors. As compared with 
preceding works on a similar topic, the methodological approach applied to this study is 
more comprehensive covering a broad range of DKT’s actions that include cellular and 







In TNBS chronic colitis model mice, the extents of inflammation and fibrotic changes were 
more prominent in TRPA1-/- knockout than in wild-type mice. One-week enema 
administration of DKT suppressed fibrotic lesions in wild-type mice, but not in TRPA1 
knockout mice. Active ingredients of DKT, induced Ca2+ influxes in InMyoFib, which were 
antagonized by TRPA1 channel blocker HC-030031. DKT counteracted TGF-β1-induced 
expression of Type 1 collagen, α-SMA, and this was accompanied by attenuated 
fibrosis-associated signaling. A DKT’s active ingredient Japanese Pepper increased the 
mRNA and protein expressions of TRPA1, which in turn negatively regulated collagen 
synthesis in InMyoFibs. In stenotic regions of CD patient’s intestines, TRPA1 expression 
was significantly increased. However, several limitations remain in this study that may 
compromise the value and relevance of this study, which include the inability of TNBS to 
create a severe phenotype of chronic colitis, the lack of control data from human healthy 
donors, and no comparative data from other Chinese (herbal) medicines that may have 
similar actions.   
 
Research conclusions 
DKT-induced expression and activation of TRPA1 could be important mechanisms for 
suppressing intestinal fibrosis, which would in part account for the reported beneficial 
actions of DKT on inflamed intestines. Thus, targeting myofibroblast TRPA1 may serve as a 
new and promising therapeutic strategy for fibrotic stenotic changes occurring in incurable 
chronic inflammatory bowel diseases such as Crohn’ disease and ulcerative colitis. 
 
Research perspectives 
Our findings not only provide a novel molecular target for the anti-fibrotic therapy of 
inflammatory bowel diseases in the future, but also a framework to reinterpret the unique 
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Figure 1 Chronic 2, 4, 6-trinitrobenzenesulfonic acid-induced colitis models of wild-type 
and transient receptor potential ankyrin 1-knockout mice. Chronic colitis was induced by 
weekly intrarectal injection of TNBS for six weeks. Immediately after the final TNBS 
treatment, a DKT enema was administered daily for one week. A: schematic presentation of 
TNBS injection and DKT enema. B: Hematoxylin–eosin (HE)- and Masson's trichrome 
(MT)-stained tissues from the vehicle control, TNBS and TNBS+DKT groups of WT and 
TRPA1-/- mice. TNBS: 2, 4, 6-trinitrobenzenesulfonic acid; WT: Wild-type; TRPA1: 
Transient receptor potential ankyrin 1; TRPA1-/-: Transient receptor potential ankyrin 






Figure 2 Fibrotic changes in wild-type and transient receptor potential ankyrin 
1-knockout CRISPR mice treated with 2, 4, 6-trinitrobenzenesulfonic acid and/or 
Daikenchuto. A: Type Ⅰ collagen expression was examined by western blotting. The ratio 





0.01 vs vehicle control, bP < 0.01 vs TNBS (n = 6). B: Fibrosis scores based on histological 
examination ranging from 0 (no fibrosis) to 3 (severe fibrosis) are shown as the dot-plot 
graph. The leftmost circles (n = 8) show absolutely zero values. Values are the means ± SD. 
C: Co-localization of TRPA1 and HSP47 proteins in the mouse intestine. WT vehicle control, 
WT TNBS: Immunostaining images of mouse intestine stained with anti-TRPA1 (red) 
antibody, anti-HSP47 (green), and DAPI (blue). Cell number per 10 mm2 is summarized in 
right graph, aP < 0.05 vs vehicle control (n = 6). TNBS: 2, 4, 6-trinitrobenzenesulfonic acid; 
WT: Wild-type; HSP47: Heat shock protein 47; TRPA1: Transient receptor potential ankyrin 






Figure 3 Daikenchuto-induced Ca2+ influx via transient receptor potential ankyrin 1 and 
anti-fibrosis effects in intestinal myofibroblasts. A: Method for ethanol-extraction of DKT 
and its components, i.e., ginger, Japanese pepper, and ginseng. B: Representative traces of 
whole-cell currents recorded from InMyoFibs cells at a holding potential of −60 mV. TRPA1 
nonselective cation currents are activated by AITC (10 μM) and inhibited by HC-030031 (10 





extracts (0.1%), which evoked prominent increases in [Ca2+]i. The TRPA1 antagonist 
HC-030031 (10 µmol/L) was added to examine whether the [Ca2+]i response involved the 
activation of TRPA1 channels. Respective data points represent means ± SEM from > 30 
cells. D: Immunostaining images of InMyoFibs with anti-α-SMA (green) antibody and 
DAPI (blue) in untreated controls, 24 h TGF-β1 (5 ng/mL) treatment, or 24 h TGF-β1 (5 
ng/mL) + DKT extracts (0.1%) treatment. E and F: DKT extracts (0.001, 0.01, and 0.1%) were 
co-administered with TGF-β1, and acta2 (α-SMA), myocd (myocardin), and col1a1 mRNA 
expression levels were quantified by real-time PCR. G: Concentrations of Type I collagen in 
the culture medium were measured by ELISA from the control and TGF-β1-treated cells. 
aP<0.05 vs TGF-β1-treated cells (n = 4). DKT extracts (0.001, 0.01, and 0.1%) were 
co-administered with TGF-β1. DKT: Daikenchuto; InMyoFibs: Intestinal myofibroblasts; 
TRPA1: Transient receptor potential ankyrin 1; AITC: Allyl isothiocyanate; α-SMA: 






   
Figure 4 Crude components/ingredient of Daikenchuto induce Ca2+ responses via the 
transient receptor potential ankyrin 1 channel with anti-fibrotic effects in intestinal 
myofibroblasts. A, B, C and D: Representative [Ca2+]i responses in InMyoFibs cells. Cells 
were exposed to ginger (0.1%), Japanese pepper (0.1%), 6-shogaol (10 µM), or 
hydroxy-α-sanshool (1 µM), which evoked measurable increases in [Ca2+]i. E and F: Cells 





AITC evoked a measurable increase in [Ca2+]i in InMyoFib. The vertical axis indicates the 
340/380 fluorescence ratio. Respective data points represent means ± SEM from > 30 cells. 
G: Ginger (0.1%) or Japanese pepper (0.1%) suppressed TGF-β1-induced α-SMA expression 
in InMyoFibs. Immunostaining images of InMyoFibs with anti-α-SMA (green) antibody 
and DAPI (blue), and no treatment or 24 h TGF-β1 (5 ng/mL) treatment. AITC: Allyl 
isothiocyanate; InMyoFib: Intestinal myofibroblast; α-SMA: α-Smooth muscle actin; 






Figure 5 Daikenchuto components/ingredients suppress increased expression of 
α-smooth muscle actin and collagen by transforming growth factor-β1. ACTA2 and 
COL1A1 mRNAs were quantified by real-time PCR in control and TGF-β1-treated (5 
ng/mL, 24 h) InMyoFibs. A, B and C: DKT components Ginger (0.1%), Japanese pepper 





hydroxy-α-sanshool (1 µM) and ginsenoside Rb1 (100 µM) (C) were co-administered with 
TGF-β1. AITC (10 µM) was used as the reference of full TRPA1 activation. D: 
Phosphorylation of Smad-2 was measured by western blot analysis. 1, 3, or 5 μmol/L 
6-shogaol was co-administered with TGF-β1. Relative expression of Smad-2 protein 
(normalized to β-actin) in TGF-β1-treated cells is shown as the ratio of the two in the 
histogram. E and F: COL1A1 and ACTA2 mRNAs were quantified by RT-PCR in TGF-β1 
treated InMyoFibs and normalized to 18S rRNA. 1, 3 or 5 μmol/L 6-shogaol was 
co-administered with TGF-β1. aP < 0.05 vs control cells; bP < 0.05 vs TGF-β1-treated cells (n 
= 4). TGF-β1: Transforming growth factor-β1; InMyoFibs: Intestinal myofibroblasts; DKT: 






Figure 6 Daikenchuto upregulates transient receptor potential ankyrin 1 expression and 
suppresses phosphorylation events downstream of transforming growth factor-β1 
signaling. A: trpa1 mRNA expression quantified by real-time PCR in control and 
TGF-β1-treated (5 ng/mL, 24 h) InMyoFibs (normalized to 18S rRNA). DKT extracts (0.001, 
0.01, 0.1%) were applied for 24 h. B: Relative mRNA expression of trpa1 with ginger (0.1%), 
ginseng radix (0.1%), Japanese pepper (0.1%), or DKT (0.1%) plus co-administered TGF-β1. 





expression and phosphorylation of Smad-2 or p38-MAPK with and without TGF-β1 
treatment at various concentrations of DKT extracts (0.001, 0.01, and 0.1%). The upper panel 
shows actual immunoblots. Graphs show relative expression level of TRPA1 (normalized to 
β-actin) and the relative ratios of phosphorylated/unphosphorylated Smad-2 and 
p38-MAPK (normalized to β-actin) after 1 h TGF-β1 treatment at various DKT 
concentrations. aP < 0.05 vs control cells, bP < 0.05 vs TGF-β1-treated cells (n = 4). TGF-β1: 
Transforming growth factor-β1; InMyoFibs: Intestinal myofibroblasts; DKT: Daikenchuto; 







Figure 7 Extracellular collagen upregulates transient receptor potential ankyrin 1 
expression to exert anti-fibrotic effects. A: Type I collagen solution (0, 0.1, or 1 µg/mL) 
was added into the culture medium, and immunoblotting was performed to detect TRPA1 
and Type I collagen expression in InMyoFibs. The rightmost graph shows the summary (n 
= 4). B–E: Relative expression levels (shown as the post/pre ratio) of col1a1, trpa1, myocd, 
and acta2 mRNAs quantified by RT-PCR in Type I collagen- or TGF-β1-treated InMyoFibs. 
In E, InMyoFibs were pre-treated with TRPA1 siRNA. aP < 0.05 vs control cells; bP < 0.05 vs 
TGF-β1-treated cells (n = 4). TRPA1: Transient receptor potential ankyrin 1; InMyoFibs: 






Figure 8 Hematoxylin–eosin, Masson’s trichrome staining. TRPA1-DAB, and 
HSP47-DAB-stained non-stenosis/stenosis surgical tissue from the transverse colon of a CD 
patient. TRPA1: Transient receptor potential ankyrin 1; DAB: Diaminobenzidine; HSP47: 







Figure 9 Graphical abstract. 
